Ruth O’Regan - Concepedia

Author

Ruth O’Regan

Also Known As

Berry, Donald A., R M O'Regan, R O'REGAN, R O'Regan, R. M. O'Regan, R. M. O’Regan, R. O'Regan, R. O’Regan, R.M. O'Regan, R. M. O'Regan

277

Publications

15.6K

Citations

H-Index

Concepts

All Affiliations

Emory University University of Wisconsin Carbone Cancer Center University of Wisconsin–Madison Northwestern University The University of Texas MD Anderson Cancer Center

About

Ruth O’Regan is an author at Emory University specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	44	5.6K
2	Health Sciences	10	10	2.4K
3	Engineering	3	3	869
4	Nursing	2	2	1.7K
5	Public Health	2	2	75

Ruth O’Regan

Publications

12.3K

Citations

H-Index

Page 1

	Year	Citations
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Journal of the National Comprehensive Cancer Network NursingSurgical OncologyBreast OncologyCancer ScreeningMedicine	2018	1.6K
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Journal of the National Comprehensive Cancer Network	2020	1.6K
NCCN Guidelines Insights: Breast Cancer, Version 1.2017 William J. Gradishar, Benjamin O. Anderson, Ronald Balassanian, Journal of the National Comprehensive Cancer Network Preclinical TherapeuticsEndocrine OncologyRadiation MedicineSurgical OncologyBreast Oncology	2017	538
Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer Xiaoxian Li, Jing Yang, Limin Peng, Breast Cancer Research and Treatment Surgical OncologyOncologyBreast OncologyNon-triple-negative Breast CancerPathology	2016	528
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial Nancy U. Lin, Virginia F. Borges, Carey K. Anders, Journal of Clinical Oncology	2020	521
Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry Yun Xing, Qaiser Chaudry, Christopher Shen, Nature Protocols NanoparticlesEngineeringNanomaterialsNanotechnologyNanobiotechnology	2007	518
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy Zahi Mitri, Tina Constantine, Ruth O’Regan Chemotherapy Research and Practice	2012	515
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Fabrice André, Ruth O’Regan, Mustafa Özgüroğlu, The Lancet Oncology Advanced Breast CancerBreast OncologyOncologyPlacebo-controlled Phase 3Clinical Trials	2014	489
Proton-Sponge Coated Quantum Dots for siRNA Delivery and Intracellular Imaging Maksym Yezhelyev, Lifeng Qi, Ruth O’Regan, Journal of the American Chemical Society	2008	404
Insulin-like Growth Factor-I–Dependent Up-regulation of ZEB1 Drives Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells Tisheeka Graham, Haiyen E. Zhau, Valerie Odero-Marah, Cancer Research	2008	383

Page 1